We also demonstrate that targeting PLOD2 enables inhibition of EGFR phosphorylation activation in ccRCC cells, suggesting a potential therapeutic strategy for ccRCC patients. The gene discussed is PLOD2; the disease is nonpapillary renal cell carcinoma.